Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

6.470 +0.120 (+1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,149,945
Open 6.310
Bid (Size) 6.150 (1)
Ask (Size) 6.500 (1)
Prev. Close 6.350
Today's Range 6.130 - 6.490
52wk Range 2.300 - 7.390
Shares Outstanding 60,069,512
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Earnings Scheduled For March 18, 2025
Via Benzinga

Performance

YTD
+48.4%
+48.4%
1 Month
N/A
N/A
3 Month
+65.5%
+65.5%
6 Month
+107.4%
+107.4%
1 Year
+154.7%
+154.7%

More News

Read More
Unusual volume stocks are being observed in Tuesday's session.
Via Chartmill
Trevi Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Trevi Therapeutics
Via Benzinga
Trevi Therapeutics's Earnings: A Preview
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
Via Benzinga
Top movers in Monday's pre-market session
Via Chartmill
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
Via Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
Via Benzinga
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
Via Benzinga
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Via MarketBeat
Exposures Product Safety
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 20, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For November 9, 2023
Via Benzinga
Earnings Scheduled For August 10, 2023
Via Benzinga

Frequently Asked Questions

Is Trevi Therapeutics, Inc. - Common Stock publicly traded?
Yes, Trevi Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Trevi Therapeutics, Inc. - Common Stock trade on?
Trevi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Trevi Therapeutics, Inc. - Common Stock?
The ticker symbol for Trevi Therapeutics, Inc. - Common Stock is TRVI on the Nasdaq Stock Market
What is the current price of Trevi Therapeutics, Inc. - Common Stock?
The current price of Trevi Therapeutics, Inc. - Common Stock is 6.470
When was Trevi Therapeutics, Inc. - Common Stock last traded?
The last trade of Trevi Therapeutics, Inc. - Common Stock was at 04/25/25 04:00 PM ET
What is the market capitalization of Trevi Therapeutics, Inc. - Common Stock?
The market capitalization of Trevi Therapeutics, Inc. - Common Stock is 388.65M
How many shares of Trevi Therapeutics, Inc. - Common Stock are outstanding?
Trevi Therapeutics, Inc. - Common Stock has 389M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.